"Granite Bio, armed with â¬87.6M funding, aims to create groundbreaking antibodies addressing inflammatory and autoimmune conditions, marking a significant advancement in biotech."
"Didomi's â¬72M funding from Marlin Equity partners will enhance its technology to help organizations optimize user choice and streamline marketing across multiple platforms."
"First Momentum Ventures has successfully closed its â¬35M Fund II to support early-stage startups in Industrial Tech and Deep Tech, fostering innovation in Europe."
"Oryzon Genomics, a clinical-stage biopharmaceutical firm, has recently completed a â¬30M capital raise to further its research in epigenetics, indicating ongoing growth in biopharmaceuticals."
The article outlines recent funding developments in the biotech and tech sectors, including Granite Bio's emergence with â¬87.6M to develop antibodies for inflammatory diseases, Didomi's â¬72M funding for enhancing user choice technology, and First Momentum Ventures' closing of â¬35M Fund II for early-stage investment in Industrial and Deep Tech. Additionally, Oryzon Genomics successfully raised â¬30M to advance its epigenetic research. These updates underline the rapid innovation and investment in these industries.
Read at Silicon Canals
Unable to calculate read time
Collection
[
|
...
]